Medartis Holding AG / Key word(s): Half Year Results PRESS RELEASE Release of an ad hoc announcement pursuant to Art. 53 LR. The issuer is solely responsible for the content of this announcement. Basel, 20 August 2024 <div><ul><li><span>Underlying group sales growth of 13.1% CER; growth including 3</span><span style="vertical-align: super;">rd</span><span> party manufacturing of 10.8% CER resulting in reported net sales of CHF 111.5m</span></li><li><span>The underlying US business achieved YoY growth of 20.6%, followed by EMEA with 17.8%; growth in APAC and LATAM lower than expected with 3.1% and -9.5% YoY respectively – Australia was affected by further government-imposed price cuts while Brazil faced a change in the private insurance sector that caused a decline in elective procedures</span></li><li><span>Improved gross margin of 80.3% (H1 2023: 77.2%), driven mainly by better manufacturing efficiency in Basel and higher volumes</span></li><li><span>EBITDA margin excluding 3</span><span style="vertical-align: super;">rd</span><span>-party manufacturing and further non-recurring items improved to 17.2% (H1 2023: 13.2%), without compromising ongoing investments into key growth markets; underlying EBIT margin doubled to 4.9%</span></li><li><span>Reported profitability was 21.4% on EBITDA level and 3.1% on EBIT, impacted by a one-off amortization of intangible assets and the related release of a contingent liability</span></li><li><span>Cash position strengthened following the issuance of a convertible bond in April 2024 – financing for potential acquisition of Keri Medical secured</span></li><li><span>Successful global launch of Foot 2 System, CCS line extensions and Scaphoid plates; further launches planned for H2 2024</span></li><li><span>Continuous strengthening of key functions through hiring, internal development and transfer of talents into US</span></li><li><span>Guidance revised for FY: 12-15% CER growth for the underlying business; around 15% underlying EBITDA margin at CER</span></li></ul><p><span style="font-style: italic;"> </span></p><p><span>CEO </span><span style="font-weight: bold;">Christoph Brönnimann</span><span> said: “I am happy to share that our two largest markets have once again delivered strong growth in H1 2024. We faced some market challenges in APAC and LATAM but our weakness there is being addressed and we expect better performance in both regions in H2. We have also maintained profitability and cash management discipline – and so I feel that this is a good moment for me to hand over to my successor, Matthias Schupp, later this year and wish him and the Medartis team all the best going forward.”</span></p><p>
</p><p><span style="font-weight: bold;">SELECTED KEY FIGURES*</span></p><p><span> </span></p><table cellspacing="0" cellpadding="0" border="0"><tbody><tr><td style="vertical-align: bottom;"><p><span>in CHF m</span></p></td><td style="vertical-align: bottom;"><p><span>H1 2024</span></p><p><span>as reported</span></p></td><td style="vertical-align: bottom;"><p><span>H1 2024 excl.</span></p><p><span>one-off items</span><span style="vertical-align: super;">1)</span></p></td><td style="vertical-align: bottom;"><p><span style="font-style: italic;">Ad info</span></p><p><span>H1 2023</span></p><p><span>as reported</span></p></td><td style="vertical-align: bottom;"><p><span>YoY growth as reported %</span></p></td></tr><tr><td style="vertical-align: top;"><p><span>Group Net Sales</span></p></td><td style="vertical-align: top;"><p><span>111.5</span></p></td><td style="vertical-align: top;"><p><span>111.5</span></p></td><td style="vertical-align: top;"><p><span>103.3</span></p></td><td style="vertical-align: top;"><p><span>7.9%</span></p></td></tr><tr><td style="vertical-align: top;"><p><span>Group Net Sales excl. 3rd Party Manufacturing</span></p></td><td style="vertical-align: top;"><p><span>107.6</span></p></td><td style="vertical-align: top;"><p><span>107.6</span></p></td><td style="vertical-align: top;"><p><span>97.6</span></p></td><td style="vertical-align: top;"><p><span>10.2%</span></p></td></tr><tr><td style="vertical-align: top;"><p><span> </span><span>EMEA</span></p></td><td style="vertical-align: top;"><p><span>59.5</span></p></td><td style="vertical-align: top;"><p><span>59.5</span></p></td><td style="vertical-align: top;"><p><span>51.5</span></p></td><td style="vertical-align: top;"><p><span>15.5%</span></p></td></tr><tr><td style="vertical-align: top;"><p><span> </span><span>US</span></p></td><td style="vertical-align: top;"><p><span>23.2</span></p></td><td style="vertical-align: top;"><p><span>23.2</span></p></td><td style="vertical-align: top;"><p><span>19.9</span></p></td><td style="vertical-align: top;"><p><span>16.6%</span></p></td></tr><tr><td style="vertical-align: top;"><p><span> </span><span>APAC</span></p></td><td style="vertical-align: top;"><p><span>15.6</span></p></td><td style="vertical-align: top;"><p><span>15.6</span></p></td><td style="vertical-align: top;"><p><span>15.8</span></p></td><td style="vertical-align: top;"><p><span>-1.3%</span></p></td></tr><tr><td style="vertical-align: top;"><p><span> </span><span>LATAM</span></p></td><td style="vertical-align: top;"><p><span>9.4</span></p></td><td style="vertical-align: top;"><p><span>9.4</span></p></td><td style="vertical-align: top;"><p><span>10.5</span></p></td><td style="vertical-align: top;"><p><span>-10.5%</span></p></td></tr><tr><td style="vertical-align: top;"><p><span>Gross Profit</span></p></td><td style="vertical-align: top;"><p><span>89.6</span></p></td><td style="vertical-align: top;"><p><span>89.6</span></p></td><td style="vertical-align: top;"><p><span>79.7</span></p></td><td style="vertical-align: top;"><p><span>12.4%</span></p></td></tr><tr><td style="vertical-align: top;"><p><span> </span><span>% of net sales</span></p></td><td style="vertical-align: top;"><p><span>80.3%</span></p></td><td style="vertical-align: top;"><p><span>80.3%</span></p></td><td style="vertical-align: top;"><p><span>77.2%</span></p></td><td style="vertical-align: top;"><p><span> </span></p></td></tr><tr><td style="vertical-align: top;"><p><span>Operating Profit (EBIT)</span></p></td><td style="vertical-align: top;"><p><span>3.5</span></p></td><td style="vertical-align: top;"><p><span>5.5</span></p></td><td style="vertical-align: top;"><p><span>2.1</span></p></td><td style="vertical-align: top;"><p><span>63.1%</span></p></td></tr><tr><td style="vertical-align: top;"><p><span> </span><span>% of net sales</span></p></td><td style="vertical-align: top;"><p><span>3.1%</span></p></td><td style="vertical-align: top;"><p><span>4.9%</span></p></td><td style="vertical-align: top;"><p><span>2.1%</span></p></td><td style="vertical-align: top;"><p><span> </span></p></td></tr><tr><td style="vertical-align: top;"><p><span>Net Profit</span></p></td><td style="vertical-align: top;"><p><span>2.6</span></p></td><td style="vertical-align: top;"><p><span>4.6</span></p></td><td style="vertical-align: top;"><p><span>-0.8</span></p></td><td style="vertical-align: top;"><p><span>n/m</span></p></td></tr><tr><td style="vertical-align: top;"><p><span> </span><span>% of net sales</span></p></td><td style="vertical-align: top;"><p><span>2.3%</span></p></td><td style="vertical-align: top;"><p><span>4.1%</span></p></td><td style="vertical-align: top;"><p><span>-0.8%</span></p></td><td style="vertical-align: top;"><p><span> </span></p></td></tr><tr><td style="vertical-align: top;"><p><span>EBITDA</span></p></td><td style="vertical-align: top;"><p><span>23.9</span></p></td><td style="vertical-align: top;"><p><span>16.3</span></p></td><td style="vertical-align: top;"><p><span>12.4</span></p></td><td style="vertical-align: top;"><p><span>92.7%</span></p></td></tr><tr><td style="vertical-align: top;"><p><span> </span><span>% of net sales</span></p></td><td style="vertical-align: top;"><p><span>21.4%</span></p></td><td style="vertical-align: top;"><p><span>14.6%</span></p></td><td style="vertical-align: top;"><p><span>12.0%</span></p></td><td style="vertical-align: top;"><p><span> </span></p></td></tr><tr><td style="vertical-align: top;"><p><span>Operating & Investment CF before M&A and Financing</span></p></td><td style="vertical-align: top;"><p><span>2.2</span></p></td><td style="vertical-align: top;"><p><span>2.2</span></p></td><td style="vertical-align: top;"><p><span>-11.9</span></p></td><td style="vertical-align: top;"><p><span>n/m</span></p></td></tr><tr><td style="vertical-align: top;"><p><span> </span><span>% of net sales</span></p></td><td style="vertical-align: top;"><p><span>2%</span></p></td><td style="vertical-align: top;"><p><span>2%</span></p></td><td style="vertical-align: top;"><p><span>-11.5%</span></p></td><td style="vertical-align: top;"><p><span> </span></p></td></tr></tbody></table><p><span style="vertical-align: super;">1)</span><span> resulting from impairment of NSI product technology and milestone payment contingent liability</span></p><p>
</p><p><span style="font-weight: bold;">REGIONAL PERFORMANCE</span></p><p><span> </span></p><p><span>In </span><span style="font-weight: bold;">EMEA</span><span> Medartis continued to perform very well, achieving overall growth of 17.8% and double digits in all countries. The DACH region grew 17%, led by Germany with 19%. Southern Europe, composed of France and Spain, grew more than 21%. The UK achieved almost 20% growth, while Poland and the 29 distributor markets attained 19%. EMEA benefited from the solid performance of Keri Medical products, which Medartis sells as a distributor in Germany, Austria and the UK and which fit perfectly into the hand and wrist portfolio, allowing cross-selling in both directions.</span></p><p><span>In the </span><span style="font-weight: bold;">US</span><span> Medartis grew by 20.6%. Monthly run rates have increased consistently, generated by the direct sales force and 57 independent distributors with 276 sales agents. The key growth driver in the US was the hand and wrist segment, driven mainly by Medartis’ flagship distal radius plates, as well as the distribution of KeriFlex and Field Orthopedics products. Growth of acquired NSI products has been slow as it is taking longer than expected to convert customers to instrument-guided Lapidus procedures. The US is building up commercial channels as a priority, focusing on fostering sales excellence by further bolstering the team with new additions in product management, marketing and medical education, and also by intensifying training and education activities.</span></p><p><span> </span></p><p><span>In </span><span style="font-weight: bold;">APAC </span><span>Medartis grew</span><span style="font-weight: bold;"></span><span>+3.1% YoY, with significant impacts from additional price cuts in Australia’s private insurance sector in H1. While volume growth was around 10%, value growth was fairly flat. The impact on reimbursements placed increasing strain on the hospital sector, patient waiting lists and the medical technology market. In late H1, Medartis prepared for the launch of Keri Touch in Australia, for which it recently received regulatory approval, and an initial cad lab was conducted with Medartis’ and Keri Medical’s worldwide faculty members. Dedicated field trainers and the sales force are currently being built up to support the launch. In Japan, the direct business more than doubled YoY, while the transition from the former distributor business to direct sales with a parallel switch into sterile products is ongoing and expected to further accelerate growth. Japanese surgeons have also shown very strong interest in the education offering from Medartis’ alliance with IBRA. Although the absolute size of the distributor markets (excl. Japan) remains small, they achieved solid growth, despite some headwind due to Korean surgeon strikes.</span></p><p><span> </span></p><p><span>Finally, in </span><span style="font-weight: bold;">LATAM</span><span> Medartis declined -9.5% YoY after facing some notable challenges. In Brazil, the largest health insurers in the private insurance sector merged, which means that since February Medartis has had to re-negotiate pricing with hospitals directly. This has led to a decline in elective procedures that are subject to a complex pre-approval process. Furthermore, there have been delays in the regulatory approval of new products. These factors have significantly affected performance, with negative growth of 27% in H1. Mexico also grew slower than expected, largely because of a reduction in government purchases around the election period. Distributor markets, however, were up 13% – despite challenges in Colombia and Argentina due to healthcare system changes and government adjustments – with strong growth in Costa Rica, in particular.</span></p><p>
</p><p><span> </span></p><p><span style="font-weight: bold;">BUSINESS SEGMENT PERFORMANCE</span></p><p><span style="font-weight: bold;"> </span></p><p><span>Growth H1 2024 @CER (excl. 3rd Parties):</span></p><table cellspacing="0" cellpadding="0" border="0"><tbody><tr><td style="vertical-align: bottom;"><p><span> </span></p></td><td style="vertical-align: bottom;"><p><span>EMEA</span></p></td><td style="vertical-align: bottom;"><p><span>APAC</span></p></td><td style="vertical-align: bottom;"><p><span>LATAM</span></p></td><td style="vertical-align: bottom;"><p><span>Nordamerika</span></p></td><td style="vertical-align: bottom;"><p><span>Total</span></p></td></tr><tr><td style="vertical-align: bottom;"><p><span>Upper Extremities</span></p></td><td style="vertical-align: bottom;"><p><span>14.7%</span></p></td><td style="vertical-align: bottom;"><p><span>-3.5%</span></p></td><td style="vertical-align: bottom;"><p><span>4.8%</span></p></td><td style="vertical-align: bottom;"><p><span>20.0%</span></p></td><td style="vertical-align: bottom;"><p><span style="font-weight: bold;">12.0%</span></p></td></tr><tr><td style="vertical-align: bottom;"><p><span>Lower Extremities</span></p></td><td style="vertical-align: bottom;"><p><span>25.4%</span></p></td><td style="vertical-align: bottom;"><p><span>21.1%</span></p></td><td style="vertical-align: bottom;"><p><span>4.0%</span></p></td><td style="vertical-align: bottom;"><p><span>10.8%</span></p></td><td style="vertical-align: bottom;"><p><span style="font-weight: bold;">20.7%</span></p></td></tr><tr><td style="vertical-align: bottom;"><p><span>CMF and Others</span></p></td><td style="vertical-align: bottom;"><p><span>26.6%</span></p></td><td style="vertical-align: bottom;"><p><span>8.0%</span></p></td><td style="vertical-align: bottom;"><p><span>-30.9%</span></p></td><td style="vertical-align: bottom;"><p><span>35.4%</span></p></td><td style="vertical-align: bottom;"><p><span style="font-weight: bold;">12.1%</span></p></td></tr><tr><td style="vertical-align: bottom;"><p><span>Total</span></p></td><td style="vertical-align: bottom;"><p><span>17.8%</span></p></td><td style="vertical-align: bottom;"><p><span>3.1%</span></p></td><td style="vertical-align: bottom;"><p><span>-9.5%</span></p></td><td style="vertical-align: bottom;"><p><span>20.6%</span></p></td><td style="vertical-align: bottom;"><p><span style="font-weight: bold;">13.1%</span></p></td></tr></tbody></table><p><span style="font-weight: bold;"> </span></p><p><span>In the first half of 2024, Medartis generated CHF 72.8m net sales through the upper extremities business, amounting to 68% of total revenues. 19% of sales (CHF 20.0m) were generated with products in the lower extremities segment, with cranio-maxillofacial and other products and services accounting for the remaining 14%.</span></p><p><span style="font-weight: bold;"> </span></p><p><span style="font-weight: bold;">Upper extremities: </span><span>Buoyed by Keri Medical, in EMEA the hand and wrist segment contributed 33% to overall sales. Upper extremities, which also includes clavicle, shoulder, forearm and elbow, continued to grow by a further 15% YoY despite already having a high share of the market. In the US, KeriFlex, which was introduced about one-and-a-half years ago, grew significantly and boosted overall sales in the hand segment to 26%. Medartis’ US wrist business accelerated to almost 20% growth, driven mainly by distal radius products. In APAC, the negative growth in upper extremities was driven by distributor markets and Australia, where the distal radius portfolio’s underlying volume growth remained at almost 10% but was affected in value terms by further price cuts. Meanwhile, growth in upper extremities amounted to over 500% in Japan, but the absolute size of this business is still small.</span></p><p><span style="font-weight: bold;"> </span></p><p><span style="font-weight: bold;">Lower extremities: </span><span>The launch of a new foot system accelerated sales in EMEA and APAC, where CCS screws also bolstered performance. The US performed below expectations in this segment, growing just under 11%. Feedback from surgeons on the acquired NSI technology remains positive, but conversion of new doctors is taking longer than planned while channel building is also progressing slower than expected. Medartis US will continue to invest in training and education as well as marketing to better address these challenges. Japan meanwhile recorded strong growth in lower extremities.</span></p><p><span> </span></p><p><span style="font-weight: bold;">CMF:</span><span> The transition from Modus 1 to Modus 2 according to MDR requirements in EMEA has accelerated sales and led to 28% CMF growth in the region. Meanwhile, the CMF business in LATAM declined 31% as a result of the changes in the Brazilian insurance system.</span></p><p><span> </span></p><p><span style="font-weight: bold;">3</span><span style="font-weight: bold; vertical-align: super;">rd</span><span style="font-weight: bold;"> party manufacturing</span><span>: This business, which was taken over as part of the acquisition of NSI, is decreasing according to plan. While Medartis will fulfill existing contracts, it will make use of available capacity to gradually increase production of its own products.</span></p><p>
</p><p><span> </span></p><p><span style="font-weight: bold;">PRODUCT DEVELOPMENT AND INNOVATION</span></p><p><span> </span></p><p><span>Medartis continuously innovates in order to further deepen its product portfolio across core strategic segments in extremities and CMF. During the first six months in 2024, the company launched a number of new products and line extensions.</span></p><p><span style="font-weight: bold; font-style: italic;"> </span></p><p><span style="font-weight: bold;">Midfoot 2.8, Mid- and Hindfoot 2.8/3.5 & Fusion 3.5 System: </span><span>Medartis launched new additions to its foot portfolio, including a unique sales kit with comprehensive training content and promotional material for three different indications.</span></p><p><span> </span></p><p><span>The expansion of the Hallux and Midfoot System 2.8 offers surgeons enhanced flexibility, precision, and adaptability with coverage of several new indications and a variety of plate sizes. The Mid- and Hindfoot System 2.8/3.5 provides an unparalleled level of surgical precision and control through unique independent plate and wedge positioning. The Fusion 3.5 System not only empowers surgeons with excellent precision in compressing individual joints but also offers a tailored and versatile range of adaptable plates.</span></p><p><span style="font-weight: bold; font-style: italic;"> </span></p><p><span style="font-weight: bold;">CCS Extensions: </span><span>In May, the CCS System was extended with additional fully threaded screws, new lengths and an improved thread design, offering a technologically advanced solution. The screw can now also be used as an intramedullary fixation solution for the metacarpals – a procedure that is trending in many markets – offering surgeons an alternative to external plate fixations both for upper as well as lower extremity fractures.</span></p><p><span style="font-weight: bold;"> </span></p><p><span style="font-weight: bold;">Scaphoid plate</span><span>: In June, Medartis’ successful and unique scaphoid plate portfolio was extended with two additional sizes to better cater for differences in scaphoid size and shape.</span></p><p><span style="font-weight: bold;"> </span></p><p><span style="font-weight: bold;">Dorsal olecranon plates:</span><span> In July the company started a limited rollout of its new dorsal olecranon plates, complementing the existing elbow portfolio to close an indication gap. The design is set apart by its anatomical shape, soft tissue protection and solid fixation of the coronoid. The full launch is planned for H1 2025.</span></p><p>
</p><p><span> </span></p><p><span style="font-weight: bold;">STRENGTHENING OF KEY FUNCTIONS THROUGH NEW HIRES AND TRANSFERS IN THE US AND GLOBALLY</span></p><p><span style="font-weight: bold;"> </span></p><p><span>Over the last six months, Medartis has hired and also relocated a number of key talents to further accelerate US growth and continue to professionalize and build a stronger and more agile organization. In March Inge Maes joined Medartis as its new CHRO, bringing exceptional expertise and experience of leading global HR functions to the Executive Management Board. Moreover, various senior positions in Global Surgeon Relations and Market Development, Marketing, Training and Education, Field Training as well as Global Supply Chain, Purchasing, PMO Management, Finance and IT were filled. In addition, some employees with deep knowledge and long-standing experience have relocated from Basel to the US to support product management, operations and manufacturing.</span></p><p><span> </span></p><p><span style="font-weight: bold;">OPERATIONAL AND FINANCIAL PERFORMANCE</span></p><p><span style="font-weight: bold;"> </span></p><p><span>In H1 Medartis achieved a gross margin of 80.3%, an improvement of 310 bps compared with H1 2023. This improvement mostly stems from increased operating efficiency in Basel’s production, including the introduction of new sterile and non-sterile packaging, bringing significant unit cost savings, a reduction in scrapping expenses as well as higher agility and lower lead time in the supply chain. The gross margin was also positively affected by the reduction in volume of the 3</span><span style="vertical-align: super;">rd</span><span> party manufacturing business which Medartis took over from NSI as part of the acquisition. Excluding the 3</span><span style="vertical-align: super;">rd</span><span>-party manufacturing business, the gross margin was 83.4%. As planned, this business, which has a much lower gross margin than Medartis, is phasing out over the next 12-18 months and will therefore have less dilution impact on the blended gross margin going forward. Approx. 50 bps of the improvement is due to the non-repetition of one-off costs following the IT hack in May 2023. These positive effects were partially reduced by an increase in Keri Medical product sales, which – as long as Medartis remains only a distributor of this business – have a lower margin than its own products.</span></p><p><span> </span></p><p><span>Operating expenses were managed through continued strong cost discipline across the company. The US has started to gain better cost efficiency as it grows, while management continues to invest in improving sales channels, training and education and back-office process stability. Set management has further improved YoY and will allow better capital efficiency going forward. In Japan, Medartis has incurred a significant spend of around CHF 3.5m in taking over the business of a former distributor. While cost efficiency in EMEA remained high, the cost ratios for LATAM and APAC decreased slightly following the unexpected top line decline in Brazil and Australia due to the insurance merger and price cuts respectively. Medartis will monitor the situation carefully over the next six to 12 months before implementing any potential cost reduction measures.</span></p><p><span> </span></p><p><span>The reported EBITDA margin of 21.4% temporarily increased due to a one-off effect related to the acquisition of the former NSI technology portfolio. As the launch of certain products is taking longer than expected, the value of some intangible assets had to be impaired, resulting in a one-off non-cash expense of CHF 9.6m. This was partially offset by the release of a contingent liability relating to a milestone payment to former NSI shareholders for NSI products sales in 2025. Excluding these items, the underlying EBITDA margin was 14.6%. Adjusted for further non-core and one-off items it even reached 17.2%. On an EBIT level, the Group achieved 4.9% for the underlying excl. NSI revaluation and 7.1% excluding other non-core and one-off items. Underlying profitability is in line with management expectations and guidance which assumed a higher top line in LATAM and APAC.</span></p><p><span> </span></p><p><span>Medartis achieved a net profit of CHF 2.6m in H1 vs a reported net loss of CHF 0.8m in H1 2023. The net profit also includes interest expenses of about 6.1% from the issuance of the CHF 115.8m convertible bond in April, of which only 3% is cash effective.</span></p><p><span> </span></p><p><span>Operating cash flow before M&A and financing improved significantly year-on-year and finished at CHF 2.2m vs CHF -11.9m in H1 2023. The NSI related re-valuation of contingent liabilities as well as intangible asset values in H1 2024 had no cash impact. As of June 2024, Medartis’ cash position is CHF 127.1m, allowing for a potential full acquisition of Keri Medical in the next 12 months. Any decisions regarding this acquisition will be made by Medartis’ Board of Directors based on Keri Medical’s operative and financial performance during 2024.</span></p><p><br/><span style="font-weight: bold;">GUIDANCE FOR THE FULL YEAR</span><span style="font-weight: bold;"> </span></p><p><span> </span></p><p><span>Given that growth in the first half-year in LATAM and APAC was lower than expected, Medartis is adjusting its guidance for the full year 2024. While the Group remains confident in its ability to outperform the underlying market, full-year growth is expected to be between 12-15% at CER.</span><span> </span><span> </span></p><p><span> </span></p><p><span>Profitability levels of the underlying EBITDA should further improve in the second half of the year and thus allow Medartis to achieve around 15% at current exchange rates for the full year, depending on top line development.</span><span> </span></p><p><span> </span></p><p><span style="font-weight: bold;">____________________________________________________________________________________</span></p><p><span> </span></p><p><span style="font-weight: bold;">Audio webcast with Q&A</span></p><p><span>Today at 11.00 a.m. there will be an audio conference to present the half-year results 2024. The speakers will be CEO Christoph Brönnimann and CFO Dirk Kirsten. The conference language is English. The presentation, the half-year report and later the recording of the event will be available on the </span><span data-tobf='blank' data-lobf='v4fox4ar=NTAxlaImpT9vQWEyXR9wpoKmpyE=k8Ew7TBwBbHxNROxQVUnBqTxBj/vl8AmQeByl8Hdh3Oa2iqbh07m9fAmhxLnYfAnk0AapiPnYf5c2f7bYn/8B0Lx2MEmp0ovkTJlpA/dhZRbOVRbYiBxpAonjTEnYPrwpRAmBTPxCbAlpbKwlRt19xMbYaPah3P=hxNnh6Ib2nBaNoRc2aL=hZqb9n5ahxMb2aomgn5x4WHvkb5y2AKwATJmkPAdkRAyQau'Out', 'eqs', '47688385');" class='js-l-obf link link--blue'><span style="text-decoration: underline;">Medartis website</span></span><span>. The presentation will be followed by a Q&A session.</span></p><p><span>Please use the </span><span data-tobf='blank' data-lobf='v4fox4ar=NTAxlaImpT9vQWEyXR9wpoKmpyE=k8Ew7TBwBbHxNROxQVUnBqTxBj/vl8AmQeByl8HdhaLbOxom93NchiRmpiOb9ZRmOn9akmRm96MbOxMcY0/8B0Lx2MEmp0ovkTJlpA/dhZRbOVRbYiBxpAonjTEnYPrwpRAmBTPxCbAlpbKwlRt19xMbYaPah3P=hxNnh6Ib2nBaNoRc2aL=hZqb9n5ahxMb2aomgn5x4WHvkb5y2AKwATJmkPAdkRAyQau'Out', 'eqs', '47688385');" class='js-l-obf link link--blue'><span style="text-decoration: underline;">webcast link</span></span><span> to follow the slide presentation and submit questions in writing. To participate directly in the conference call and ask questions verbally, you will need to </span><span data-tobf='blank' data-lobf='v4fox4ar=NTAxlaImpT9vQWEyXR9wpoKmpyE=k8Ew7TBwBbHxNROxQVUnBqTxBj/vl8AmQeByl8HdhxLbpmobBn9bBn7bkj9bkZNapmLmpionYf7n2iOa2878B0Lx2MEmp0ovkTJlpA/dhZRbOVRbYiBxpAonjTEnYPrwpRAmBTPxCbAlpbKwlRt19xMbYaPah3P=hxNnh6Ib2nBaNoRc2aL=hZqb9n5ahxMb2aomgn5x4WHvkb5y2AKwATJmkPAdkRAyQau'Out', 'eqs', '47688385');" class='js-l-obf link link--blue'><span style="text-decoration: underline;">register</span></span><span> to receive the telephone number, a passcode and a personal PIN.</span></p><p><span> </span></p><p><span style="font-weight: bold;">Your contact:</span><span></span></p><p>
Medartis Corporate Communications <br/>
Investor contact: investor.relations@medartis.com<br/>
Media contact: corporate.communication@medartis.com<br/>
+41 61 633 37 36 / +41 61 633 37 34</p><p>
</p><p><span> </span></p><p><span style="font-weight: bold;">About Medartis</span></p><p><span>Founded in 1997 and headquartered in Basel, Switzerland, Medartis is one of the world’s leading manufacturers and providers of medical devices for surgical fixation of bone fractures for upper and lower extremities as well as for the craniomaxillofacial region. Medartis employs approx. 860 individuals across its 13 locations, with products offered in over 50 countries globally. Medartis is committed to providing surgeons and operating theatre personnel with the most innovative titanium implants and instruments as well as best-in-class service. For more information, please visit </span><span data-tobf='blank' data-lobf='v4fox4ar=NTAxlaImpT9vQWEyXR9wpoKmpyE=k8Ew7TBwBbHxNROxQVUnBqTxBj/vl8AmQeByl8Hdk6PmOiOmBmRm9mOa9aqn2fAbOA7mk6omBZoaOj9mk0A8B0Lx2MEmp0ovkTJlpA/dhZRbOVRbYiBxpAonjTEnYPrwpRAmBTPxCbAlpbKwlRt19xMbYaPah3P=hxNnh6Ib2nBaNoRc2aL=hZqb9n5ahxMb2aomgn5x4WHvkb5y2AKwATJmkPAdkRAyQau'Out', 'eqs', '47688385');" class='js-l-obf link link--blue'><span style="text-decoration: underline;">www.medartis.com</span></span><span>.</span></p><p><span> </span></p><p><span style="font-weight: bold;">Disclaimer</span></p><p><span>This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Medartis Holding AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intentions. Further, neither the company nor any of its directors, officers, employees, agents, counsel or advisers nor any other person makes any representation or warranty, express or implied, as to the accuracy or completeness of the information contained herein or of the views given or implied, and accordingly no reliance should be placed on.</span></p></div></div></div><br/><hr/>End of Inside Information<hr/></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td align="left" valign="top" nowrap="nowrap">Language:</td><td align="left" valign="top">
English</td></tr><tr><td align="left" valign="top" nowrap="nowrap">Company:</td><td align="left" valign="top">
Medartis Holding AG </td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">
Hochbergerstrasse 60E</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">
4057 Basel</td></tr><tr><td align="left" valign="top"/><td align="left" valign="top">
Switzerland</td></tr><tr><td align="left" valign="top" nowrap="nowrap">Phone:</td><td align="left" valign="top">
+41 61 633 34 34</td></tr><tr><td align="left" valign="top" nowrap="nowrap">Fax:</td><td align="left" valign="top">
+41 61 633 34 00</td></tr><tr><td align="left" valign="top" nowrap="nowrap">E-mail:</td><td align="left" valign="top">
info@medartis.com</td></tr><tr><td align="left" valign="top" nowrap="nowrap">Internet:</td><td align="left" valign="top">
www.medartis.com</td></tr><tr><td align="left" valign="top" nowrap="nowrap">ISIN:</td><td align="left" valign="top">
CH0386200239</td></tr><tr><td align="left" valign="top" nowrap="nowrap">Valor:</td><td align="left" valign="top">
38620023</td></tr><tr><td align="left" valign="top">Listed:</td><td align="left" valign="top">
SIX Swiss Exchange</td></tr><tr><td align="left" valign="top" nowrap="nowrap">EQS News ID:</td><td align="left" valign="top">
1970945</td></tr></table><br/><table border="0" cellpadding="0" cellspacing="0"><tr><td align="left" valign="top" colspan="2"/></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td align="left" valign="top" colspan="2"> </td></tr><tr><td align="left" valign="top">End of Announcement</td><td align="left" valign="top">
EQS News Service</td></tr></table><table border="0" width="600" cellpadding="0" cellspacing="0"><tr><td><hr/></td></tr></table><p>
1970945 20-Aug-2024 CET/CEST
</p><img data-zoomable="true" src="https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1970945&application_name=news&site_id=zonebourse_com~~~71435185-72e2-4ff3-98c0-1866a1714c4a" alt="fncls.ssp?fn=show_t_gif&application_id=1970945&application_name=news&site_id=zonebourse_com~~~71435185-72e2-4ff3-98c0-1866a1714c4a" width="0" height="0" border="0"/></p></div><div class="grid gbetween align-center mt-15"><div class="c-auto mb-15 txt-s2"><div></div>
© EQS -
2024
</div><div class="c-auto mb-15"><div class="dropdown-container "><span class="js_dropdown cursor-pointer c-inline " data-dropdown="#shareIt_32478"
><span class="px-15 py-10 btn btn--action--outter c-block"><i class="bi-box-arrow-up"></i> Share
</span></span><div id="shareIt_32478" class="dropdown "><div class="py-10 px-15"><div class="grid gnowrap" data-trans="Link copied"><a class="c-block c " target="popup" style="color:#0073b1"
href="https://www.linkedin.com/shareArticle?mini=true&url=https%3A%2F%2Fwww.marketscreener.com%2Fquote%2Fstock%2FMEDARTIS-HOLDING-AG-42470802%2Fnews%2FMedartis-reports-13-revenue-growth-on-Group-level-driven-by-strong-regional-growth-in-the-US-21--47688385%2F%3Futm_source%3Dlinkedin%26utm_medium%3Dsocial%26utm_campaign%3Dshare&title=Medartis reports 13%25 revenue growth on Group level, driven by strong regional growth in the US (21%25) and EMEA (18%25) –improvement of EBITDA* margin to 17%25&summary=Medartis Holding AG / Key word: Half Year Results
Medartis reports 13% revenue growth on Group level, driven by strong regional growth in the US and EMEA –improvement of EBITDA* margin to 17%...&source="
title="Share on LinkedIn"
rel="nofollow"
https://www.linkedin.com/shareArticle?mini=true&url=https%3A%2F%2Fwww.marketscreener.com%2Fquote%2Fstock%2FMEDARTIS-HOLDING-AG-42470802%2Fnews%2FMedartis-reports-13-revenue-growth-on-Group-level-driven-by-strong-regional-growth-in-the-US-21--47688385%2F%3Futm_source%3Dlinkedin%26utm_medium%3Dsocial%26utm_campaign%3Dshare&title=Medartis reports 13%25 revenue growth on Group level, driven by strong regional growth in the US (21%25) and EMEA (18%25) –improvement of EBITDA* margin to 17%25&summary=Medartis Holding AG / Key word: Half Year Results
Medartis reports 13% revenue growth on Group level, driven by strong regional growth in the US and EMEA –improvement of EBITDA* margin to 17%...&source=','popup','width=600,height=600'); return false;"
><i class="bi-linkedin txt-s4 px-5"></i></a><a class="c-block c " target="popup" style="color:#000"
href="https://x.com/intent/tweet?text=Medartis reports 13%25 revenue growth on Group level, driven by strong regional growth in the US (21%25) and EMEA (18%25) –improvement of EBITDA* margin to 17%25%20%23MarketScreener&url=https%3A%2F%2Fwww.marketscreener.com%2Fquote%2Fstock%2FMEDARTIS-HOLDING-AG-42470802%2Fnews%2FMedartis-reports-13-revenue-growth-on-Group-level-driven-by-strong-regional-growth-in-the-US-21--47688385%2F%3Futm_source%3Dtwitter%26utm_medium%3Dsocial%26utm_campaign%3Dshare"
title="Share on X"
rel="nofollow"
https://x.com/intent/tweet?text=Medartis reports 13%25 revenue growth on Group level, driven by strong regional growth in the US (21%25) and EMEA (18%25) –improvement of EBITDA* margin to 17%25%20%23MarketScreener&url=https%3A%2F%2Fwww.marketscreener.com%2Fquote%2Fstock%2FMEDARTIS-HOLDING-AG-42470802%2Fnews%2FMedartis-reports-13-revenue-growth-on-Group-level-driven-by-strong-regional-growth-in-the-US-21--47688385%2F%3Futm_source%3Dtwitter%26utm_medium%3Dsocial%26utm_campaign%3Dshare','popup','width=600,height=600'); return false;"
><i class="bi-twitter-x txt-s4 px-5"></i></a><a class="c-block c " target="popup" style="color:#25D366"
href="https://wa.me/?text=https%3A%2F%2Fwww.marketscreener.com%2Fquote%2Fstock%2FMEDARTIS-HOLDING-AG-42470802%2Fnews%2FMedartis-reports-13-revenue-growth-on-Group-level-driven-by-strong-regional-growth-in-the-US-21--47688385%2F%3Futm_source%3Dwhatsapp%26utm_medium%3Dsocial%26utm_campaign%3Dshare"
title="Share on WhatsApp"
rel="nofollow"
><i class="bi-whatsapp txt-s4 px-5"></i></a><a class="c-block c " target="popup" style="color:#0088cc"
href="https://telegram.me/share/url?url=https%3A%2F%2Fwww.marketscreener.com%2Fquote%2Fstock%2FMEDARTIS-HOLDING-AG-42470802%2Fnews%2FMedartis-reports-13-revenue-growth-on-Group-level-driven-by-strong-regional-growth-in-the-US-21--47688385%2F%3Futm_source%3Dtelegram%26utm_medium%3Dsocial%26utm_campaign%3Dshare"
title="Share on Telegram"
rel="nofollow"
><i class="bi-telegram txt-s4 px-5"></i></a><a class="c-block c " target="popup" style="color:#1877f2"
href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.marketscreener.com%2Fquote%2Fstock%2FMEDARTIS-HOLDING-AG-42470802%2Fnews%2FMedartis-reports-13-revenue-growth-on-Group-level-driven-by-strong-regional-growth-in-the-US-21--47688385%2F%3Futm_source%3Dfacebook%26utm_medium%3Dsocial%26utm_campaign%3Dshare"
title="Share on Facebook"
rel="nofollow"
https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.marketscreener.com%2Fquote%2Fstock%2FMEDARTIS-HOLDING-AG-42470802%2Fnews%2FMedartis-reports-13-revenue-growth-on-Group-level-driven-by-strong-regional-growth-in-the-US-21--47688385%2F%3Futm_source%3Dfacebook%26utm_medium%3Dsocial%26utm_campaign%3Dshare','popup','width=600,height=600'); return false;"
><i class="bi-facebook txt-s4 px-5"></i></a><a class="c-block c js-copyArticle" target="popup" style="color:#3a3a3a"
href="https://www.marketscreener.com/quote/stock/MEDARTIS-HOLDING-AG-42470802/news/Medartis-reports-13-revenue-growth-on-Group-level-driven-by-strong-regional-growth-in-the-US-21--47688385/?utm_source=copy&utm_medium=social&utm_campaign=share"
title="Share on Copy"
rel="nofollow"
><i class="bi-link-45deg txt-s4 px-5"></i></a><a class="c-block c " target="popup" style="color:#3a3a3a"
href="mailto:?subject=MarketScreener.com: Medartis reports 13%25 revenue growth on Group level, driven by strong regional growth in the US (21%25) and EMEA (18%25) –improvement of EBITDA* margin to 17%25&body=Medartis reports 13%25 revenue growth on Group level, driven by strong regional growth in the US (21%25) and EMEA (18%25) –improvement of EBITDA* margin to 17%25%0D%0A%0D%0AMedartis Holding AG / Key word: Half Year Results
Medartis reports 13% revenue growth on Group level, driven by strong regional growth in the US and EMEA –improvement of EBITDA* margin to 17%...%0D%0A%0D%0Ahttps%3A%2F%2Fwww.marketscreener.com%2Fquote%2Fstock%2FMEDARTIS-HOLDING-AG-42470802%2Fnews%2FMedartis-reports-13-revenue-growth-on-Group-level-driven-by-strong-regional-growth-in-the-US-21--47688385%2F%3Futm_source%3Demail%26utm_medium%3Dsocial%26utm_campaign%3Dshare"
title="Share on Email"
rel="nofollow"
><i class="bi-envelope-fill txt-s4 px-5"></i></a></div></div></div></div></div></div></article></div></div><div class="m-15" id="Zonebourse_Article_Video"><div
class="vsly-player media--169 bg-grey position-relative"
id="PLCHkFhqLGmYn"
data-template="PVaRF_MsC2XGj"></div></div><div class="mb-15 gcenter"><!-- VideoAnchor --><div class='zppAds'><div id='zppVideoAnchor'></div></div><script>
aAdsList.push('VideoAnchor');
aAdsListSize.push(null);
aAdsListCA.push(['US']);
</script></div><div class="card mb-15"><div class="card-header"><h3 class="card-title"><a class="link" href="/quote/stock/MEDARTIS-HOLDING-AG-42470802/news/">
Latest news about Medartis Holding AG </a></h3></div><div class="card-content"><table class="table table--small table--hover table--bordered"><tbody><tr class=" "><td class="table-child--centered table-child--top table-child--nowrap table-child--w60 txt-s1"><span class="js-date-relative txt-muted h-100 c-block px-5"
data-utc-date="2026-05-13T22:00:00+00:00"
title="06:00:00 2026-05-13 pm EDT">
May. 13</span></td><td class="w-100"><a href="/news/medartis-holding-ag-completed-the-acquisition-of-cadskills-bv-ce7f5adfdb8cf120" class="txt- txt-overflow-2 link link--no-underline my-5 my-m-0 ">
Medartis Holding AG completed the acquisition of Cadskills Bv.
</a></td><td class="table-child--right table-child--top table-child--w60 c-none cm-table"><span class="c-inline p-5 badge badge--small txt-s1" title="S&P Capital IQ"><span class="c-inline txt-align-center" style="width: 18px;">
CI
</span></span></td></tr><tr class=" "><td class="table-child--centered table-child--top table-child--nowrap table-child--w60 txt-s1"><span class="js-date-relative txt-muted h-100 c-block px-5"
data-utc-date="2026-04-23T13:00:00+00:00"
title="09:00:00 2026-04-23 am EDT">
Apr. 23</span></td><td class="w-100"><a href="/news/medartis-holding-ag-elects-yang-xu-as-board-director-and-member-of-finance-and-audit-committee-ce7f59ded080f020" class="txt- txt-overflow-2 link link--no-underline my-5 my-m-0 ">
Medartis Holding AG Elects Yang Xu as Board Director and Member of Finance and Audit Committee
</a></td><td class="table-child--right table-child--top table-child--w60 c-none cm-table"><span class="c-inline p-5 badge badge--small txt-s1" title="S&P Capital IQ"><span class="c-inline txt-align-center" style="width: 18px;">
CI
</span></span></td></tr><tr class=" "><td class="table-child--centered table-child--top table-child--nowrap table-child--w60 txt-s1"><span class="js-date-relative txt-muted h-100 c-block px-5"
data-utc-date="2026-04-17T13:56:00+00:00"
title="09:56:00 2026-04-17 am EDT">
Apr. 17</span></td><td class="w-100"><a href="/news/straumann-holding-ag-announces-board-changes-ce7f59d9de8afe2c" class="txt- txt-overflow-2 link link--no-underline my-5 my-m-0 ">
Straumann Holding AG Announces Board Changes
</a></td><td class="table-child--right table-child--top table-child--w60 c-none cm-table"><span class="c-inline p-5 badge badge--small txt-s1" title="S&P Capital IQ"><span class="c-inline txt-align-center" style="width: 18px;">
CI
</span></span></td></tr><tr class=" "><td class="table-child--centered table-child--top table-child--nowrap table-child--w60 txt-s1"><span class="js-date-relative txt-muted h-100 c-block px-5"
data-utc-date="2026-03-17T15:09:00+00:00"
title="11:09:00 2026-03-17 am EDT">
Mar. 17</span></td><td class="w-100"><a href="/news/medartis-holding-ag-reports-earnings-results-for-the-full-year-ended-december-31-2025-ce7e5ed8df8ff021" class="txt- txt-overflow-2 link link--no-underline my-5 my-m-0 ">
Medartis Holding AG Reports Earnings Results for the Full Year Ended December 31, 2025
</a></td><td class="table-child--right table-child--top table-child--w60 c-none cm-table"><span class="c-inline p-5 badge badge--small txt-s1" title="S&P Capital IQ"><span class="c-inline txt-align-center" style="width: 18px;">
CI
</span></span></td></tr><tr class=" "><td class="table-child--centered table-child--top table-child--nowrap table-child--w60 txt-s1"><span class="js-date-relative txt-muted h-100 c-block px-5"
data-utc-date="2026-03-17T11:35:59+00:00"
title="07:35:59 2026-03-17 am EDT">
Mar. 17</span></td><td class="w-100"><a href="/news/transcript-medartis-holding-ag-2025-earnings-call-mar-17-2026-ce7e5edbdf8fff20" class="txt- txt-overflow-2 link link--no-underline my-5 my-m-0 ">
Medartis Holding AG, 2025 Earnings Call, Mar 17, 2026
</a></td><td class="table-child--right table-child--top table-child--w60 c-none cm-table"><span class="c-inline p-5 badge badge--small txt-s1" title="S&P Capital IQ"><span class="c-inline txt-align-center" style="width: 18px;"><i class="bi-mic-fill txt-negative"></i></span></span></td></tr><tr class=" "><td class="table-child--centered table-child--top table-child--nowrap table-child--w60 txt-s1"><span class="js-date-relative txt-muted h-100 c-block px-5"
data-utc-date="2026-03-17T06:25:18+00:00"
title="02:25:18 2026-03-17 am EDT">
Mar. 17</span></td><td class="w-100"><a href="/news/medartis-logs-higher-fy25-net-income-revenue-ce7e5edbda8afe25" class="txt- txt-overflow-2 link link--no-underline my-5 my-m-0 ">
Medartis Logs Higher FY25 Net Income, Revenue
</a></td><td class="table-child--right table-child--top table-child--w60 c-none cm-table"><span class="c-inline p-5 badge badge--small txt-s1" title="MT Newswires"><span class="c-inline txt-align-center" style="width: 18px;">
MT
</span></span></td></tr><tr class=" "><td class="table-child--centered table-child--top table-child--nowrap table-child--w60 txt-s1"><span class="js-date-relative txt-muted h-100 c-block px-5"
data-utc-date="2026-03-17T05:52:43+00:00"
title="01:52:43 2026-03-17 am EDT">
Mar. 17</span></td><td class="w-100"><a href="/news/swiss-stocks-factors-to-watch-on-march-17-ce7e5edbda89ff25" class="txt- txt-overflow-2 link link--no-underline my-5 my-m-0 ">
Swiss stocks - Factors to watch on March 17
</a></td><td class="table-child--right table-child--top table-child--w60 c-none cm-table"><span class="c-inline p-5 badge badge--small txt-s1" title="Reuters"><span class="c-inline txt-align-center" style="width: 18px;">
RE
</span></span></td></tr><tr class=" "><td class="table-child--centered table-child--top table-child--nowrap table-child--w60 txt-s1"><span class="js-date-relative txt-muted h-100 c-block px-5"
data-utc-date="2026-03-17T05:33:24+00:00"
title="01:33:24 2026-03-17 am EDT">
Mar. 17</span></td><td class="w-100"><a href="/news/medartis-builds-on-momentum-with-16-organic-sales-growth-and-core-ebitda-margin-exceeding-18-ce7e5edbdb80ff2c" class="txt- txt-overflow-2 link link--no-underline my-5 my-m-0 ">
Medartis 2025 organic core sales grow 15.7% to CHF 266.1 million
</a></td><td class="table-child--right table-child--top table-child--w60 c-none cm-table"><span class="c-inline p-5 badge badge--small txt-s1" title="Reuters"><span class="c-inline txt-align-center" style="width: 18px;">
RE
</span></span></td></tr><tr class=" "><td class="table-child--centered table-child--top table-child--nowrap table-child--w60 txt-s1"><span class="js-date-relative txt-muted h-100 c-block px-5"
data-utc-date="2026-03-16T23:00:00+00:00"
title="07:00:00 2026-03-16 pm EDT">
Mar. 16</span></td><td class="w-100"><a href="/news/medartis-holding-ag-signed-a-definitive-agreement-to-acquire-cadskills-bv-ce7f5adfdb8cf025" class="txt- txt-overflow-2 link link--no-underline my-5 my-m-0 ">
Medartis Holding AG signed a definitive agreement to acquire Cadskills Bv.
</a></td><td class="table-child--right table-child--top table-child--w60 c-none cm-table"><span class="c-inline p-5 badge badge--small txt-s1" title="S&P Capital IQ"><span class="c-inline txt-align-center" style="width: 18px;">
CI
</span></span></td></tr><tr class=" "><td class="table-child--centered table-child--top table-child--nowrap table-child--w60 txt-s1"><span class="js-date-relative txt-muted h-100 c-block px-5"
data-utc-date="2025-11-24T06:54:35+00:00"
title="01:54:35 2025-11-24 am EST">
Nov. 24</span></td><td class="w-100"><a href="/news/medartis-names-new-finance-chief-ce7d5edcda8cf12d" class="txt- txt-overflow-2 link link--no-underline my-5 my-m-0 ">
Medartis Names New Finance Chief
</a></td><td class="table-child--right table-child--top table-child--w60 c-none cm-table"><span class="c-inline p-5 badge badge--small txt-s1" title="MT Newswires"><span class="c-inline txt-align-center" style="width: 18px;">
MT
</span></span></td></tr><tr class=" "><td class="table-child--centered table-child--top table-child--nowrap table-child--w60 txt-s1"><span class="js-date-relative txt-muted h-100 c-block px-5"
data-utc-date="2025-11-24T06:02:35+00:00"
title="01:02:35 2025-11-24 am EST">
Nov. 24</span></td><td class="w-100"><a href="/news/medartis-appoints-peter-hackel-as-new-chief-financial-officer-ce7d5edcda8bf620" class="txt- txt-overflow-2 link link--no-underline my-5 my-m-0 ">
Medartis appoints Peter Hackel as new chief financial officer
</a></td><td class="table-child--right table-child--top table-child--w60 c-none cm-table"><span class="c-inline p-5 badge badge--small txt-s1" title="Reuters"><span class="c-inline txt-align-center" style="width: 18px;">
RE
</span></span></td></tr><tr class=" "><td class="table-child--centered table-child--top table-child--nowrap table-child--w60 txt-s1"><span class="js-date-relative txt-muted h-100 c-block px-5"
data-utc-date="2025-11-23T23:00:00+00:00"
title="06:00:00 2025-11-23 pm EST">
Nov. 23</span></td><td class="w-100"><a href="/news/medartis-holding-ag-announces-cfo-changes-ce7d51dade8df426" class="txt- txt-overflow-2 link link--no-underline my-5 my-m-0 ">
Medartis Holding AG Announces CFO Changes
</a></td><td class="table-child--right table-child--top table-child--w60 c-none cm-table"><span class="c-inline p-5 badge badge--small txt-s1" title="S&P Capital IQ"><span class="c-inline txt-align-center" style="width: 18px;">
CI
</span></span></td></tr><tr class=" "><td class="table-child--centered table-child--top table-child--nowrap table-child--w60 txt-s1"><span class="js-date-relative txt-muted h-100 c-block px-5"
data-utc-date="2025-08-19T21:21:58+00:00"
title="05:21:58 2025-08-19 pm EDT">
25-08-19</span></td><td class="w-100"><a href="/news/medartis-holding-ag-reports-earnings-results-for-the-half-year-ended-june-30-2025-ce7c51ddde8af226" class="txt- txt-overflow-2 link link--no-underline my-5 my-m-0 ">
Medartis Holding AG Reports Earnings Results for the Half Year Ended June 30, 2025
</a></td><td class="table-child--right table-child--top table-child--w60 c-none cm-table"><span class="c-inline p-5 badge badge--small txt-s1" title="S&P Capital IQ"><span class="c-inline txt-align-center" style="width: 18px;">
CI
</span></span></td></tr><tr class=" "><td class="table-child--centered table-child--top table-child--nowrap table-child--w60 txt-s1"><span class="js-date-relative txt-muted h-100 c-block px-5"
data-utc-date="2025-08-19T09:20:16+00:00"
title="05:20:16 2025-08-19 am EDT">
25-08-19</span></td><td class="w-100"><a href="/news/transcript-medartis-holding-ag-h1-2025-earnings-call-aug-19-2025-ce7c51dcd080fe26" class="txt- txt-overflow-2 link link--no-underline my-5 my-m-0 ">
Medartis Holding AG, H1 2025 Earnings Call, Aug 19, 2025
</a></td><td class="table-child--right table-child--top table-child--w60 c-none cm-table"><span class="c-inline p-5 badge badge--small txt-s1" title="S&P Capital IQ"><span class="c-inline txt-align-center" style="width: 18px;"><i class="bi-mic-fill txt-negative"></i></span></span></td></tr><tr class=" "><td class="table-child--centered table-child--top table-child--nowrap table-child--w60 txt-s1"><span class="js-date-relative txt-muted h-100 c-block px-5"
data-utc-date="2025-08-19T07:43:14+00:00"
title="03:43:14 2025-08-19 am EDT">
25-08-19</span></td><td class="w-100"><a href="/news/corporate-results-schedule-for-august-19-2025-ce7c51dcd08bff22" class="txt- txt-overflow-2 link link--no-underline my-5 my-m-0 ">
Corporate results schedule for August 19, 2025
</a></td><td class="table-child--right table-child--top table-child--w60 c-none cm-table"><span class="c-inline p-5 badge badge--small txt-s1" title="MarketScreener.com"><span class="c-inline txt-align-center" style="width: 18px;"><img src="https://cdn.zonebourse.com/images/logo_at.gif" width="14" height="8" alt="Zonebourse"></span></span></td></tr></tbody></table></div></div></div><div class="c-12 cm-4 "><div class="card mb-15"><div class="card-header"><h3 class="card-title"><a class="link" href="/quote/stock/MEDARTIS-HOLDING-AG-42470802/graphics/">
Chart Medartis Holding AG </a></h3></div><div class="card-content"><div class="grid mb-15"><div class="c-auto "><label for="bWCMois">Duration</label><selectchart_ta_42470802','duration',this.value)" id="bWCMois" class="ml-5 input"><option value="8" selected>Auto.</option><option value="2">2 months</option><option value="3">3 months</option><option value="6">6 months</option><option value="9">9 months</option><option value="12">1 year</option><option value="24">2 years</option><option value="60">5 years</option><option value="120">10 years</option><option value="9999">Max.</option></select></div><div class="c-auto "><label for="bWCPer">Period</label><selectchart_ta_42470802','cycle',this.value)" id="bWCPer" class="ml-5 input"><option value="DAY" selected>Day</option><option value="WEEK">Week</option></select></div></div><div class="txt-align-center media media--43 placeholder placeholder--w"><img id="chart_ta_42470802"
data-src="https://www.marketscreener.com/zbcache/charts/ObjectChart.aspx?Name=42470802&Type=Custom&Intraday=1&Width={width}&Height={height}&Cycle=DAY1&Duration={duration}&Render=Candle&ShowCopyright=2&ShowName=0&Locale=en&ShowVolume=1&Company=Skin:ZonebourseLight&externload="
src="data:image/gif;base64,R0lGODlhAQABAAD/ACwAAAAAAQABAAACADs="
data-cycle="DAY1"
data-type="1"
alt="Chart Medartis Holding AG"
class="c-block js-responsive-ta-chart"
/></div></div><div class="card-footer"><a href="/quote/stock/MEDARTIS-HOLDING-AG-42470802/graphics/"
class="more">
MED: Dynamic Chart
</a></div></div><div id="companyProfile" class="card mb-15 card--collapsible pos-next"><span class="js-collapse collapse" data-collapse="companyProfile"></span><div class="card-header"><h2 class="card-title"><a class="link" href="/quote/stock/MEDARTIS-HOLDING-AG-42470802/company/">
Company Profile
</a></h2></div><div class="card-content"><div><div class="mb-10 txt-justify txt-overflow-6"><div style="float:left;" class="mr-10"><img
height="30"
alt="Logo Medartis Holding AG"
none'"
src="https://cdn.zonebourse.com/static/instruments-squared-42470802.png"
></div>
Medartis Holding AG is a Switzerland-based holding company of the Medartis Group, which is engaged in manufacturing medical devices and implants. The Group develops, manufactures and distributes to surgeons, hospitals and medical centers titanium screws, plates, surgical instruments and system solutions for internal fracture fixation. Medartis AG, the Company's wholly-owned subsidiary, has developed such technologies as TriLock for locking the screw into the plate, SpeedTip, a screw that does not require pre-drilling, and HexaDrive self-holding screw and screw-driver. It has two product lines. The APTUS product line comprises upper and lower extremities products for hand, wrist, elbow, shoulder and foot fixation. The MODUS line combines products dedicated to cranio-maxillofacial (CMF) surgery. The Group's products are sold globally in more than 30 countries, including Germany and the United States, either directly through its sales subsidiaries, or through third-party distributors.
</div><div class="grid pb-10 pb-m-5 border-top pt-5"><div class="c-3 txt-bold">Employees</div><div class="c-9 txt-align-right">
1,259
</div></div><div class="grid py-10 py-m-5 border-top txt"><div class="c-3 txt-bold">Sector</div><a class="c-9 txt-align-right link" href="/stock-exchange/sectors/healthcare/healthcare-services/?cf=ME5wTzZia2NKbTZkdlhjdDhhdGtyb1pnVFY4WDdvSjR6R0poRWdmMzg3bz0">
Medical Equipment, Supplies & Distribution
</a></div><div class="grid py-10 py-m-5 border-top txt"><div class="c-3 txt-bold">Calendar</div><div class="c-9 txt-align-right txt-inline"><a href="/quote/stock/MEDARTIS-HOLDING-AG-42470802/calendar/" class="link">
Earnings release - Q2 2026
</a></div></div></div></div><div class="card-footer"><a href="/quote/stock/MEDARTIS-HOLDING-AG-42470802/company/"
class="more">
More about the company
</a></div></div><div id="chart_right_ise_e_card" class="card card--collapsible mb-15 pos-next"><span class="js-collapse collapse" data-collapse="chart_right_ise_e_card"></span><div class="card-header"><h3 class="card-title"><a class="link" href="/quote/stock/MEDARTIS-HOLDING-AG-42470802/finances/">
Income Statement and Estimates
</a></h3></div><div class="card-content"><picture><source media="(max-width: 576px)" srcset="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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"><source media="(min-width: 576px) and (max-width: 768px)" srcset="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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"><source media="(min-width: 768px) and (max-width: 991px)" srcset="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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"><source media="(min-width: 992px) and (max-width: 1260px)" srcset="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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"><source media="(min-width: 1260px) and (max-width: 1400px)" srcset="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=NXlMWVoxUzNiUmVJZXhZSzZyemovWk1hR3JhWUd0c3JxdHhFb3AyMDFMMVNCY3E1TGhSOVNqcHU0Ti9MTUVRVXBFNkNobUJGdk9CSjh3SGtqaFhjdGdtOUowU0tDRnBCNnZhTDAxVnJWaDkvYnNqa0loQXZTSzRDdFZCRGpJVWk2YVFVN2E2QXFxUmNhZFBLSEhqUW1YMUFoTlNFRHRyQTBpa0kxdCtkanpTN0F0d1E0bG5lTmpmaldmV3ZabFVZTWdua2ZpZVl4Sll1ZHVuM3dyeWQydU1Wd21sT0ZEenluWi9sdC9ZbS8vOEM0U0dmVThUY2lBU0QzNzNkQTFnUGRxbzE3cTNxK2g1Nm8rdUcyeCs3NlpCNjRLem80WkYzeFlrRkthUFhDaUg1MjlJeXAxR3lIY0hDSFNJeVJKWHIrWDB0aGgyZ3NuUjFXdE92b1pqL1ZXeGZabE1hcTIrWHdNdXU1SDEyWFJRRVJ2ZnZQYnQ2RWhtQVB3Q2Z6U3dDM0lqZlJUb1NiS3lSNkh5cDFoL0FRclRxakc3WkllWk1iQkFNYmtPUm80SlpCZG1taGpHYWd6c20xeDJQS3pRTElGQXhaSEpiZWFwbmwrWXpIRGgvSzZpZGpUYlM4bjZHRS9PWERzTTloMjNtT3RKempoNElaMTFsRHNkUVNjMCtiU1ByU2FpZGNoSFpheWtGRjdKWDFRPT0"><source media="(min-width: 1400px) and (max-width: 1599px)" srcset="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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"><img src="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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" alt="" class='w-100' height='250' width='338'loading='lazy'loading")'></picture></div><div class="card-footer"><a href="/quote/stock/MEDARTIS-HOLDING-AG-42470802/finances/"
class="more">
More financial data
</a></div></div><div id="ratings" class="card mb-15 card--collapsible pos-next"><span class="js-collapse collapse" data-collapse="ratings"></span><div class="card-header"><h3 class="card-title"><a class="link" href="/quote/stock/MEDARTIS-HOLDING-AG-42470802/ratings/">
Ratings
</a></h3></div><div class="card-content"><div><div class="grid py-5 border-bottom"><div class="c"><i class="bi-star-half pr-5"></i>Trader
</div><div class="c-auto px-5"><div class="dropdown-container c-inline"><span class="js_dropdown cursor-pointer c-inline " data-dropdown="#80noteDesc_4057"
data-dropdown-hover="true"><span class="badge badge--neutral"><i class="bi-info-circle"></i></span></span><div id="80noteDesc_4057" class="dropdown dropdown--wm250 "><div class="p-10"><p class="title txt-s2">Trader</p><p>This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.</p></div></div></div></div><div class="c-f90 txt-align-center"><span title="12%" class="star star--size2 v-align-middle"></span></div></div><div class="grid py-5 border-bottom"><div class="c"><i class="bi-star-half pr-5"></i>Investor
</div><div class="c-auto px-5"><div class="dropdown-container c-inline"><span class="js_dropdown cursor-pointer c-inline " data-dropdown="#80noteDesc_4058"
data-dropdown-hover="true"><span class="badge badge--neutral"><i class="bi-info-circle"></i></span></span><div id="80noteDesc_4058" class="dropdown dropdown--wm250 "><div class="p-10"><p class="title txt-s2">Investor</p><p>This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.</p></div></div></div></div><div class="c-f90 txt-align-center"><span title="15%" class="star star--size2 v-align-middle"></span></div></div><div class="grid py-5 border-bottom"><div class="c"><i class="bi-star-half pr-5"></i>Global
</div><div class="c-auto px-5"><div class="dropdown-container c-inline"><span class="js_dropdown cursor-pointer c-inline " data-dropdown="#80noteDesc_4049"
data-dropdown-hover="true"><span class="badge badge--neutral"><i class="bi-info-circle"></i></span></span><div id="80noteDesc_4049" class="dropdown dropdown--wm250 "><div class="p-10"><p class="title txt-s2">Global</p><p>This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.</p></div></div></div></div><div class="c-f90 txt-align-center"><span title="8%" class="star star--size1 v-align-middle"></span></div></div><div class="grid py-5 border-bottom"><div class="c"><i class="bi-star-half pr-5"></i>Quality
</div><div class="c-auto px-5"><div class="dropdown-container c-inline"><span class="js_dropdown cursor-pointer c-inline " data-dropdown="#80noteDesc_4050"
data-dropdown-hover="true"><span class="badge badge--neutral"><i class="bi-info-circle"></i></span></span><div id="80noteDesc_4050" class="dropdown dropdown--wm250 "><div class="p-10"><p class="title txt-s2">Quality</p><p>This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.</p></div></div></div></div><div class="c-f90 txt-align-center"><span title="16%" class="star star--size2 v-align-middle"></span></div></div><div class="grid py-5 "><div class="c"><i class="bi-star-half pr-5"></i>ESG MSCI
</div><div class="c-auto px-5"><div class="dropdown-container c-inline"><span class="js_dropdown cursor-pointer c-inline " data-dropdown="#80noteDesc_5546"
data-dropdown-hover="true"><span class="badge badge--neutral"><i class="bi-info-circle"></i></span></span><div id="80noteDesc_5546" class="dropdown dropdown--wm250 "><div class="p-10"><p class="title txt-s2">ESG MSCI</p><p>The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.</p></div></div></div></div><div class="c-f90 txt-align-center"><div class="esg-rank esg-rank--aa txt-bold txt-align-center">AA</div></div></div></div><picture><source media="(max-width: 576px)" srcset="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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"><source media="(min-width: 576px) and (max-width: 768px)" srcset="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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"><source media="(min-width: 768px) and (max-width: 991px)" srcset="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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"><source media="(min-width: 992px) and (max-width: 1260px)" srcset="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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"><source media="(min-width: 1260px) and (max-width: 1400px)" srcset="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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"><source media="(min-width: 1400px) and (max-width: 1599px)" srcset="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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"><img src="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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" alt="" class='w-100' height='320' width='338'loading='lazy'loading")'></picture></div><div class="card-footer"><a href="/quote/stock/MEDARTIS-HOLDING-AG-42470802/ratings/" class="more">More Ratings</a></div></div><div id="consensusDetail" class="card mb-15 card--collapsible pos-next"><span class="js-collapse collapse" data-collapse="consensusDetail"></span><div class="card-header c-flex gbetween"><h2 class="card-title"><a class="link" href="/quote/stock/MEDARTIS-HOLDING-AG-42470802/consensus/">
Analysts' Consensus
</a></h2></div><div class="card-content"><div><div class="txt-align-center my-10">Sell<div class="consensus-gauge" title="Rate: 7.5 / 10"><img style="padding-left:68.5px;" src="https://cdn.zonebourse.com/images/consensus_flch.gif" alt="Consensus"></div>Buy</div><div class="grid py-5"><div class="c">Mean consensus</div><div class="c-auto txt-align-right txt-bold">OUTPERFORM</div></div><div class="grid border-top py-5"><div class="c">Number of Analysts</div><div class="c-auto txt-align-right txt-bold">4</div></div><div class="grid border-top py-5"><div class="c">Last Close Price</div><div class="c-auto txt-align-right txt-bold"><span class="last "
>72.60</span>CHF</div></div><div class="grid border-top py-5"><div class="c">Average target price</div><div class="c-auto txt-align-right txt-bold"><span class="last "
>95.97</span>CHF</div></div><div class="grid border-top py-5"><div class="c">Spread / Average Target</div><div class="c-auto txt-align-right txt-bold"><span class="variation variation--pos no-animation txt-align-center c-block "
>+32.19%</span></div></div></div></div><div class="card-footer"><a href="/quote/stock/MEDARTIS-HOLDING-AG-42470802/consensus/" class="more">Consensus</a></div></div><div id="chart_change_eps-cae" class="card card--collapsible mb-15 pos-next"><span class="js-collapse collapse" data-collapse="chart_change_eps-cae"></span><div class="card-header"><a class="card-title" href="/quote/stock/MEDARTIS-HOLDING-AG-42470802/consensus-revisions/">EPS Estimates</a></div><div class="card-content"><picture><source media="(max-width: 576px)" srcset="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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"><source media="(min-width: 576px) and (max-width: 768px)" srcset="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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"><source media="(min-width: 768px) and (max-width: 991px)" srcset="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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"><source media="(min-width: 992px) and (max-width: 1260px)" srcset="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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"><source media="(min-width: 1260px) and (max-width: 1400px)" srcset="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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"><source media="(min-width: 1400px) and (max-width: 1599px)" srcset="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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"><img src="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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" alt="" class='w-100' height='300' width='338'loading='lazy'loading")'></picture></div><div class="card-footer"><a class="more" href="/quote/stock/MEDARTIS-HOLDING-AG-42470802/consensus-revisions/">
Revisions to estimates
</a></div></div><div id="chart_qual_est" class="card card--collapsible pos-next mb-15"><span class="js-collapse collapse" data-collapse="chart_qual_est"></span><div class="card-header"><h3 class="card-title">Quarterly revenue - Rate of surprise</h3></div><div class="card-content"><picture><source media="(max-width: 576px)" srcset="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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"><source media="(min-width: 576px) and (max-width: 768px)" srcset="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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"><source media="(min-width: 768px) and (max-width: 991px)" srcset="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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"><source media="(min-width: 992px) and (max-width: 1260px)" srcset="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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"><source media="(min-width: 1260px) and (max-width: 1400px)" srcset="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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"><source media="(min-width: 1400px) and (max-width: 1599px)" srcset="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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"><img src="https://cdn.zonebourse.com/static/hes/MEDARTIS-HOLDING-AG_.svg?_=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" alt="" class='w-100' height='300' width='338'loading='lazy'loading")'></picture></div><div class="card-footer"><a class="more" href="/quote/stock/MEDARTIS-HOLDING-AG-42470802/calendar/">
Company calendar
</a></div></div></div></div><div class="mb-15 c-12 c-flex gcenter"><!-- Footer --><div class='zppAds'><div id='zppFooter'></div></div><script>
aAdsList.push('Footer');
aAdsListSize.push([[970, 250], [1000, 180], [1000, 200], [1000, 250]]);
aAdsListCA.push(null);
</script></div></main><div class="js-responsive-move-container c-none cl-block" data-move-id="rs_light_screen_content"><div class="js-responsive-move h-100" data-move-id="rs_light_screen_content" data-move-type="large"><aside class="c-none cm-block cm-f300 pt-5 h-100"><div class="rsidebar" style="margin:0;" ><script>
const RS_ASYNC = true;
</script><div class="rsidebar__component rsidebar__indexes mt-10 mt-m-0"><div class="rsidebar__indexes__menu px-5"><span data-tab="0" class="c js_rs__link link link--white rsidebar__indexes__menu__row rsidebar__indexes__menu__row--active"
><i class="bi-activity"></i> Indices</span><span data-tab="1" class="c js_rs__link link link--white rsidebar__indexes__menu__row "
>
Europe</span><span data-tab="2" class="c js_rs__link link link--white rsidebar__indexes__menu__row "
>
America</span><span data-tab="3" class="c js_rs__link link link--white rsidebar__indexes__menu__row "
>
Asia</span></div><div class="rsidebar__indexes__container"><div class="rsidebar__indexes__container__tab rsidebar__indexes__container__tab--active"><div class="txt-align-center px-m-5 p-5 my-10 bg-graph-intra-dark" style="height:116.8px"><div class="js_rs__graph placeholder" style="height:100px;width: 290px;"></div></div><div class="pb-10"><div class="quotation_table"><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div></div></div></div></div></div><div class="my-15"><!-- Right2 --><div class='zppAds'><div id='zppRight2'></div></div><script>
aAdsList.push('Right2');
aAdsListSize.push([300, 600]);
aAdsListCA.push(null);
</script></div><div id="rs-watchlist" class="mt-15"><div class="rsidebar__component pb-10"><div class="c-flex gbetween align-center p-10"><a href="/watchlist" class="rsidebar__title mt-0 txt-white">My Watchlist</a><div class="c ml-15 js-rs-watchlist placeholder">
</div></div><div class="quotation_table"><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div></div><hr /><div class="quotation_table"><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div></div></div><a href="/watchlist" class="c-block pl-0 py-5 txt-s2 more">My lists</a></div><div id="rs-palmares-0" class="mt-15"><div class="rsidebar__component pb-10"><div class="c-flex gbetween align-center p-10"><span class="rsidebar__title mt-0 txt-white placeholder">Rankings</span><div class="c ml-15 js-rs-watchlist placeholder">
</div></div><div class="quotation_table"><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div></div><hr /><div class="quotation_table"><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div></div><div class="pt-5"><div class="chart chart--h150 placeholder bg-black-primary"></div></div></div><a href="#"
class="c-block pl-0 py-5 txt-s2 more placeholder">
More Rankings
</a></div><div id="rs-palmares-1" class="mt-15"><div class="rsidebar__component pb-10"><div class="c-flex gbetween align-center p-10"><span class="rsidebar__title mt-0 txt-white placeholder">Rankings</span><div class="c ml-15 js-rs-watchlist placeholder">
</div></div><div class="quotation_table"><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div></div><hr /><div class="quotation_table"><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div></div><div class="pt-5"><div class="chart chart--h150 placeholder bg-black-primary"></div></div></div><a href="#"
class="c-block pl-0 py-5 txt-s2 more placeholder">
More Rankings
</a></div><div class="rsidebar__component js-rs-quotes mt-10 mt-m-0"><p class="rsidebar__title px-10 pt-10 pb-5 m-0">Currency / Forex</p><div class="txt-align-center px-m-5 p-5 bg-graph-intra-dark" style=""><div class="js_rs__graph placeholder" style="height:100px;width: 290px;"></div></div><div class="pb-10"><div class="quotation_table"><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div></div></div></div><div class="rsidebar__component js-rs-quotes mt-10 mt-m-0"><p class="rsidebar__title px-10 pt-10 pb-5 m-0">Commodities</p><div class="txt-align-center px-m-5 p-5 bg-graph-intra-dark" style=""><div class="js_rs__graph placeholder" style="height:100px;width: 290px;"></div></div><div class="pb-10"><div class="quotation_table"><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div></div></div></div><div class="rsidebar__component js-rs-quotes mt-10 mt-m-0"><p class="rsidebar__title px-10 pt-10 pb-5 m-0">Cryptocurrencies</p><div class="txt-align-center px-m-5 p-5 bg-graph-intra-dark" style=""><div class="js_rs__graph placeholder" style="height:100px;width: 290px;"></div></div><div class="pb-10"><div class="quotation_table"><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div></div></div></div><div class="rsidebar__component js-rs-quotes mt-10 mt-m-0"><p class="rsidebar__title px-10 pt-10 pb-5 m-0">Interest Rates</p><div class="txt-align-center px-m-5 p-5 bg-graph-intra-dark" style=""><div class="js_rs__graph placeholder" style="height:100px;width: 290px;"></div></div><div class="pb-10"><div class="quotation_table"><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div><div class="quotation_table__row px-5 placeholder"></div></div></div></div></aside></div></div></div><div class="bcrumb"><ol itemscope itemtype="https://schema.org/BreadcrumbList"><li itemprop="itemListElement" itemscope itemtype="https://schema.org/ListItem"><a itemprop="item" itemid="https://www.marketscreener.com/" href="/"><span itemprop="name">Stock Market</span></a><meta itemprop="position" content="1"></li><li itemprop="itemListElement" itemscope itemtype="https://schema.org/ListItem"><a itemprop="item" itemid="https://www.marketscreener.com/stock-exchange/shares/" href="/stock-exchange/shares/"><span itemprop="name">Equities</span></a><meta itemprop="position" content="2"></li><li itemprop="itemListElement" itemscope itemtype="https://schema.org/ListItem"><a itemprop="item" itemid="https://www.marketscreener.com/quote/stock/MEDARTIS-HOLDING-AG-42470802/" href="/quote/stock/MEDARTIS-HOLDING-AG-42470802/"><span itemprop="name"> MED Stock
</span></a><meta itemprop="position" content="3"></li><li itemprop="itemListElement" itemscope itemtype="https://schema.org/ListItem"><a itemprop="item" itemid="https://www.marketscreener.com/quote/stock/MEDARTIS-HOLDING-AG-42470802/news/" href="/quote/stock/MEDARTIS-HOLDING-AG-42470802/news/"><span itemprop="name">News Medartis Holding AG</span></a><meta itemprop="position" content="4"></li><li itemprop="itemListElement" itemscope itemtype="https://schema.org/ListItem"><span itemprop="name">Medartis reports 13% revenue growth on Group level, driven by strong regional growth in the US (21%) and EMEA (18%) –improvement of EBITDA* margin to 17%</span><meta itemprop="position" content="4"></li></ol></div></div></div><footer><div class="container"><div class="grid gbetween align-center border-bottom--black mb-15 pb-15"><div class="pos-1 c c-none cs-block"><div class="txt-align-center"><img src="https://cdn.zonebourse.com/static/resize/40/40//images/services/2023/footer_logoass_portail.png" width="40" height="40"
alt="Best financial portal"
loading="lazy"
/></div><p class="m-0 txt-align-center txt-white txt-bold txt-s2 my-5">
Best financial<br/> portal
</p></div><div class="pos-3 c-6 cxs"><div class="txt-align-center"><img src="https://cdn.zonebourse.com/static/resize/40/40//images/services/2023/footer_logoass_2001_en.png" width="40" height="40"
alt="More than 20 yearsat your side"
loading="lazy"/></div><p class="m-0 txt-align-center txt-white txt-bold txt-s2 my-5">
More than 20 years<br/>at your side
</p></div><div class="c-6 cxs pos-5"><div class="txt-align-center js-l-obf cursor-pointer" data-tobf='blank' data-lobf="v4fox4ar=NToxCjOy4WEw2To=BbKwgTNnlnEnlxKwk0NvpjoxpbNnkjJnl6JmpTIdQboml8Odhiu"><img src="https://cdn.zonebourse.com/static/resize/106/48//static/images/footer/img_footer_trustpilot_4.png" loading="lazy" width="106" height="48" alt="Trustpilot"/></div></div><div class="c-6 cxs pos-3 pos-xs-7 mb-25 mb-s-0"><div class="txt-align-center"><img src="https://cdn.zonebourse.com/static/resize/40/40//images/services/2023/footer_logoass_membresl.png" width="40" height="40"
loading="lazy"
alt="+ 1,300,000members"/></div><p class="m-0 txt-align-center txt-white txt-bold txt-s2 my-5">
+ 1,300,000<br/>members
</p></div><div class="c c-none cs-block pos-6"><div class="txt-align-center"><img src="https://cdn.zonebourse.com/static/resize/40/40//images/services/2023/footer_logoass_resilitaion.png" width="40" height="40"
loading="lazy"
alt="Quick & easycancellation"/></div><p class="m-0 txt-align-center txt-white txt-bold txt-s2 my-5">
Quick & easy<br/>cancellation
</p></div><div class="c c-none cm-block pos-8"><div class="txt-align-center"><img src="https://cdn.zonebourse.com/static/resize/40/40//images/services/2023/footer_logoass_experts.png" width="40" height="40"
loading="lazy"
alt="Our Expertsare here for you"
/></div><p class="m-0 txt-align-center txt-white txt-bold txt-s2 my-5">
Our Experts<br/>are here for you
</p></div></div><div class="grid my-15 py-10 align-center"><div class="c-12 cs mr-auto c-flex align-center gcenter gs-start"><span class="js-l-obf cursor-pointer c-block cs-none cm-block" data-tobf='blank' data-lobf="v4fox4ar=NTq=BbKwgTbml8GnlfOmQ8AnkRAx9Zu"><i class="bi-twitter-x txt-white txt-s4 mr-15"></i></span><span class="js-l-obf cursor-pointer c-block cs-none cm-block" data-tobf='blank' data-lobf="v4fox4ar=NTQyQxJzkTPy4j7ngR9wpoKeZP5xBIAy0b9xBjAwBjN"><i class="bi-youtube txt-white txt-s4 mr-15"></i></span><span class="js-l-obf cursor-pointer c-block cs-none cm-block" data-tobf='blank' data-lobf="v4fox4ar=NTQyQxJvkROy20CxB0I=BbKwgTIml8GnlfOmQ8AnkRAxBTBnBA9vk0H=Luu"><i class="bi-instagram txt-white txt-s4 mr-15"></i></span><span class="js-l-obf cursor-pointer c-block cs-none cm-block" data-tobf='blank' data-lobf="v4fox4ar=NTQyQxJw2AJvpj/vkqJmpTI=pbKwlW5wC/Kwk0NvpjoxpbNnkjJnl6K"><i class="bi-linkedin txt-white txt-s4 mr-15"></i></span><span class="js-l-obf cursor-pointer c-block cs-none cm-block" data-tobf='blank' data-lobf="v4fox4ar=NTQyQxJy2AGy2TG=BbKwgTVwk0NvpjoxpbNnkjJnl6JmpTI"><i class="bi-tiktok txt-white txt-s4 mr-15"></i></span><span class="js-l-obf cursor-pointer" data-tobf='blank' data-lobf="v4fox4ar=NT5x4WO=B0Lx2MA=BbKwgTPxNT5x4VKwk0NvpjoxpbNnkjJnl6KvkePbOeOcYxochxu"><img src="https://cdn.zonebourse.com/static/images/footer/img_footer_appstore.png" alt="Download from Apple Store" loading="lazy"/></span></div><div class="c-12 cs-auto my-25 my-s-0"><div class="c-flex txt-white txt-s2 align-center gcenter"><div class="c"><p class="m-0">OUR EXPERTS ARE HERE FOR YOU</p><p class="m-0 txt-bold" >Monday - Friday 9am-12pm / 2pm-6pm GMT + 1</p></div><div class="pl-10 c-auto"><span class="js_modal_button" data-modal="contact-us" style="cursor:pointer;"><span class="btn btn--footer">Contact us</span></span><div id="contact-us" class="modal modal--large modal--no-refresh "
><span class="js_modal_close modal__close-btn"contact-us')"><i class="bi-x txt-s6 txt-black"></i></span><div class="modal__content h-100"><!--<iframe width="100%" class="media media--1610" src="/mods_a/popup/popup_contact.php"frameborder="0"></iframe>--></div></div></div></div></div><div class="c ml-auto txt-align-center txt-align-s-right"><div class="p-m-15 pr-10"><span class="js-l-obf cursor-pointer" data-lobf="=Luu"><img src="https://cdn.zonebourse.com/static/images/footer/footer_logo_ms.png" width="218" height="21" alt="MarketScreener, Stock Market Live" loading="lazy"/><span></div></div></div><div class="grid gcenter txt-footer mt-30"><span class="js-l-obf cursor-pointer c-auto" data-tobf='blank' data-lobf="=pMAnp0H=kRKy2A9neuu">
Legal information
</span><span class="c-none cs-inline ml-5 mr-5 c-auto">|</span><span class="cursor-pointer"
show', 2, console.log, {jumpAt: 'privacy'});">
Cookie settings
</span><span class="c-none cs-inline ml-5 mr-5 c-12 cs-auto" >|</span><span class="js-l-obf cursor-pointer c-auto" data-tobf='blank' data-lobf="=p8HwpxK">
MarketScreener Blog
</span><span class="c-none cs-inline ml-5 mr-5 c-12 cs-auto" >|</span><a href="/about-us" class="link txt-footer">
About us
</a><span class="c-none cs-inline ml-5 mr-5 c-12 cs-auto" >|</span><span class="c-block cs-inline txt-align-center" >
Copyright © 2026 Surperformance SAS. All rights reserved.
</span></div><div class="txt-align-center txt-footer mt-10">
Stock quotes are provided by Factset, Morningstar and S&P Capital IQ
</div></div></footer><script data-action="javascript-global-variable">
const GLOBAL_LOCALE = "en_US";
const GLOBAL_LANG = "en";
const GLOBAL_ISMOBILE = false;
const GLOBAL_TIMEZONE = "America/New_York"
const GLOBAL_XID = ""
const GLOBAL_ENV = 'PROD';
const GLOBAL_COLOR_SCHEME = 'light';
</script><script data-version='external' src=https://cdnjs.cloudflare.com/ajax/libs/jquery/3.7.1/jquery.min.js></script><script data-version='external' src=https://securepubads.g.doubleclick.net/tag/js/gpt.js></script><script data-version='external' id=xieg6Sie src=https://cdn.viously.com/js/sdk/boot.js></script><script data-version='external' src=https://cdnjs.cloudflare.com/ajax/libs/highcharts/12.3.0/highstock.min.js></script><script data-version='external' src=https://cdnjs.cloudflare.com/ajax/libs/highcharts/12.3.0/modules/treemap.min.js></script><script data-version='external' src=https://cdnjs.cloudflare.com/ajax/libs/highcharts/12.3.0/modules/heatmap.min.js></script><script data-version='external' src=https://cdnjs.cloudflare.com/ajax/libs/highcharts/12.3.0/highcharts-more.min.js></script><script data-version='external' src=https://cdn.appconsent.io/loader.js></script><script data-version='external' src=https://www.googletagmanager.com/gtag/js?id=G-W5MZBYLHSG></script><script data-version='external' src=https://cdnjs.cloudflare.com/ajax/libs/socket.io/4.8.1/socket.io.min.js></script><script data-version='external' src=https://accounts.google.com/gsi/client></script><script data-version='v1779441044' src="https://cdn.zonebourse.com/static/compiled-js/prod-1779441044-12250bd13a4782ac206952327ef0342d.min.js"></script><script>
__tcfapi('init', 2,
function() {
__tcfapi('show', 2, console.log, {jumpAt: 'banner',lazy: true});
__tcfapi("addEventListener", 2,
function (tcData, success) {
if(success && tcData.eventStatus === 'tcloaded' && tcData.addtlConsent === null) {
console.log("show CMP");
__tcfapi('show', 2, console.log);
}
}
);
},
{
appKey: '5eef9679-6e01-4486-8a2f-e0bdb1912916',
urlRedirect: {
main: {
denyAll : '/services/solutions/?utmzb_campaign=cmp++popin_cmp_refuser-s-abonner+refuser-s-abonner+&utmzb_content=++++&utmzb_source=popin&utmzb_medium=url_declenchement',
continueWithoutAccepting : '/services/solutions/?utmzb_campaign=cmp++popin_cmp_refuser-s-abonner+refuser-s-abonner+&utmzb_content=++++&utmzb_source=popin&utmzb_medium=url_declenchement',
},
settings : {
denyAll : '/services/solutions/?utmzb_campaign=cmp++popin_cmp_refuser-s-abonner+refuser-s-abonner+&utmzb_content=++++&utmzb_source=popin&utmzb_medium=url_declenchement',
}
},
}
)
</script><script data-action="{} Tags init"> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); function gaEvent(eventCategory, eventAction, eventLabel, eventValue) { var eventConf = {}; eventConf['send_to'] = 'G-W5MZBYLHSG'; if (typeof eventCategory !== 'undefined') eventConf['event_category'] = eventCategory; if (typeof eventLabel !== 'undefined') eventConf['event_label'] = eventLabel; if (typeof eventValue !== 'undefined') eventConf['value'] = eventValue; gtag('event',eventAction,eventConf); } </script><div id='div-gpt-ad-pixel' style="position:fixed;bottom:0;pointer-events: none"></div><script>
googletag.cmd.push(()=>{
googletag.defineSlot('/4093671/__pixel__', [1, 1], 'div-gpt-ad-pixel').addService(googletag.pubads())
googletag.pubads().enableSingleRequest();
googletag.enableServices();
})
</script><script type="text/javascript" src="https://try.abtasty.com/c08aeadc32b24da5aeee48542ac7879a.js"></script><script>
window.dataLayer = window.dataLayer || [];
window.dataLayer.push({
'userStatus': 'Gratuit',
});
</script><span class="js_modal_button" data-modal="user_data_modal" style="cursor:pointer;"></span><div id="user_data_modal" class="modal modal--large p-0 "
><div class="modal__content "></div><div class="modal__footer"></div></div><div class="esi_h" id="ud" style="width:0;margin:0;height:0;overflow:hidden;"><!-- bActiveMobileVersion 0 --><!-- bIsMobile 0 -->
<div
data-ga_event="onLinkClick"
data-ga_categorie="stats_teasing_click"
data-ga_action="867"
><div style="display:none;"
data-ga_event="onload"
data-ga_categorie="stats"
data-ga_action="teasing"
data-ga_libelle="867"></div><div style="display:none;"
data-ga_event="onload"
data-ga_categorie="sticky-btn-light"
data-ga_action="non-inscrit"
data-ga_libelle="sticky-btn-light_non-inscrits_meilleurs-outils_bg-bleu"></div><div id="t867" style="display:block"><div id="teasing_867" style="position:fixed;bottom:0;left:0px;width:100%;z-index:998;" >
<div style="align-items: start;display:flex;font-size: 0.9rem;padding:7px;background:#004eff;color:#ffffff;">
<div style="flex:1;display:flex;justify-content: center;">
<a target="_top" style="flex:1;display:flex;justify-content: center;text-decoration:none;color:inherit;"
href="/signup?utmzb_campaign=non-inscrits++sticky-btn-light_non-inscrits_meilleurs-outils_bg-bleu+meilleurs-outils_bg-bleu+&utmzb_content=++++&utmzb_source=sticky-btn-light&utmzb_medium=url_declenchement">
<div style="align-self: center;margin-right: 5px;">
<span style="
">
The best tools reserved for subscribers to boost the performance of your investments! </span>
<span class="c-inline cs-none" >
<div style="
color:#ffffff; font-weight:700; ">
Optimize my profits </div>
</span>
</div>
<div class="c-none cs-block" >
<div style="
box-shadow:1px 1px 2px #5c5c5c; padding:3px 15px; color:#000000; background:#ffffff; margin:0px 0px 0px 15px; ">
Optimize my profits </div>
</div> </a>
</div>
<div class="ajax_close_teasing867" style="padding:0px 10px;">
<svg
class="bi bi-x-circle-fill "
xmlns="http://www.w3.org/2000/svg" style="margin-top:5px;cursor:pointer;margin-left:auto;width:20px;" fill="white" alt="fermer"
viewBox="0 0 16 16">
<path
data-idteasing="867"
class="ajax_close_teasing867"
d="M16 8A8 8 0 1 1 0 8a8 8 0 0 1 16 0zM5.354 4.646a.5.5 0 1 0-.708.708L7.293 8l-2.647 2.646a.5.5 0 0 0 .708.708L8 8.707l2.646 2.647a.5.5 0 0 0 .708-.708L8.707 8l2.647-2.646a.5.5 0 0 0-.708-.708L8 7.293 5.354 4.646z"/>
</svg>
</div>
</div>
</div>
<script>
document.addEventListener("click", function(event) {
if (event.target.matches(".ajax_close_teasing867")) {
var element = event.target;
var xhr = new XMLHttpRequest();
xhr.open("GET", "/mods_a/ajax_teasing.php?action=hide&idT="+element.getAttribute('data-idteasing'), true);
xhr.setRequestHeader("Content-Type", "application/json");
xhr.onreadystatechange = function() {
if (xhr.readyState === 4 && xhr.status === 200) {
element.closest('[id*="teasing_"]').remove();
}
};
xhr.send();
}
});
document.addEventListener("click", function(event) {
if (event.target.matches(".ajax_close_teasing_ws867")) {
var element = event.target;
element.closest('[id*="teasing_"]').remove();
}
});
</script>
</div></div></div><script>
function onloadUI()
{
}
function onunloadUI()
{
}
</script>
<script>var country_location = "IN";
function startAdsServiceD(){
gaEvent('adspv', 'internal_start', 'IN');
$(document).ready(function() {
displayViewableAds('internal');
$( window ).scroll(function() {
displayViewableAds('internal');
});
});
}
$(document).ready(function() {gaEvent('adspv', 'internal', 'IN');});
googletag.cmd.push(function() {
googletag.pubads().setTargeting('Edition', 'en_US');
googletag.pubads().setTargeting('UserType', 'free');
googletag.pubads().setTargeting('Content', 'equities');
googletag.pubads().setTargeting('codezb', '42470802');
var iAdsPos = 0; aAdsList.forEach(function(e) { if (aAdsListSize[iAdsPos] !== null && (aAdsListCA[iAdsPos] === null || aAdsListCA[iAdsPos] == country_location)) { googletag.defineSlot('/4093671/_'+e+'_/internal_'+e, aAdsListSize[iAdsPos], 'zpp'+e).addService(googletag.pubads());}iAdsPos++;});
googletag.enableServices();
var iAdsPos = 0; aAdsList.forEach(function(e) { if (aAdsListSize[iAdsPos] !== null && (aAdsListCA[iAdsPos] === null || aAdsListCA[iAdsPos] == country_location)) { googletag.display('zpp'+e); }iAdsPos++;});
try{googletag.pubads().getSlots().forEach(function(slot){if(slot.getSlotElementId().startsWith('zpp')){;}else{googletag.pubads().refresh([slot],{changeCorrelator: false});}})}catch(error){console.error(error)}
});
$(document).ready(function() { $( document).on('zbv_visible',function () {startAdsService();}); if (document[zbv_hidden]===false) { startAdsService(); } });
</script> </div><script async defer src="https://ats-wrapper.privacymanager.io/ats-modules/7b190444-c935-406d-8261-160ca079fd9a/ats.js"></script><script data-action="{} Tags usage" data-version="3" data-type="cached">
gtag('config', 'G-W5MZBYLHSG', { 'anonymize_ip': true, 'page_path': "/quote/stock/MEDARTIS-HOLDING-AG-42470802/news/Medartis-reports-13-revenue-growth-on-Group-level-driven-by-strong-regional-growth-in-the-US-21--47688385/"
, 'content_group1': 'Actions' , 'content_group2': 'eqs' , 'content_group3': 'action/communique_de_presse' });
</script><script data-action="live-opts">
const liveHtml_BASE_URL = "https://live.marketscreener.com";
const liveHtml_AUTH = { hkKey: "d9f7754e11c1f2f2360da0cbe529016f", pvKey: "7644daf4a6a6059f9d74d7eb092450b7", uKey:"L3F1b3RlL3N0b2NrL01FREFSVElTLUhPTERJTkctQUctNDI0NzA4MDIvbmV3cy9NZWRhcnRpcy1yZXBvcnRzLTEzLXJldmVudWUtZ3Jvd3RoLW9uLUdyb3VwLWxldmVsLWRyaXZlbi1ieS1zdHJvbmctcmVnaW9uYWwtZ3Jvd3RoLWluLXRoZS1VUy0yMS0tNDc2ODgzODUv" };
const liveHtml_TOJS = [];
</script><div id="editionModal" class="modal modal--large "><span class="js_modal_close modal__close-btn"editionModal')"><i class="bi-x txt-s7 txt-black"></i></span><div class="modal__content"><div class="modal_title-custom pt-15"><div class="grid align-center"><i class="pl-10 bi-globe2 globe-icon c-none cm-inline"></i><div><p class="pl-10 txt-bold m-0">Select your edition</p><p class="txt-s1 txt-muted m-0 pl-10">All financial news and data tailored to specific country editions</p></div></div></div><div class="grid mb-5 mt-15"><div class="c-12 cm-3 c-flex gcol gbetween"><div class="mb-10"><p class="region-title pl-5 mb-10">NORTH AMERICA</p><div class="c-flex flex-wrap countries-grid--1"><a class="country-item align-center active" data-edition="en_US" href="/"><div class="country-flag"><img src="https://cdn.zonebourse.com/images/png-country/24x24/us.png" loading="lazy" alt="MarketScreener"></div><span class="country-name">United-States</span></a><a class="country-item align-center " data-edition="en_CA" href="//ca.marketscreener.com/"><div class="country-flag"><img src="https://cdn.zonebourse.com/images/png-country/24x24/ca.png" loading="lazy" alt="MarketScreener Canada"></div><span class="country-name">Canada</span></a></div></div><div class="mb-10"><p class="region-title pl-5 mb-10">MIDDLE EAST</p><div class="c-flex flex-wrap countries-grid--1"><a class="country-item align-center " data-edition="en_SA" href="//sa.marketscreener.com/"><div class="country-flag"><img src="https://cdn.zonebourse.com/images/png-country/24x24/sa.png" loading="lazy" alt="MarketScreener Saudi Arabia"></div><span class="country-name">Saudi Arabia</span></a><a class="country-item align-center " data-edition="en_AE" href="//ae.marketscreener.com/"><div class="country-flag"><img src="https://cdn.zonebourse.com/images/png-country/24x24/ae.png" loading="lazy" alt="MarketScreener UAE Emirates"></div><span class="country-name">United Arab Emirates</span></a></div></div></div><div class="c-12 cm-6 "><div class="mb-10"><p class="region-title pl-5 mb-10">EUROPE</p><div class="c-flex flex-wrap countries-grid--2"><a class="country-item align-center " data-edition="fr_FR" href="//www.zonebourse.com/"><div class="country-flag"><img src="https://cdn.zonebourse.com/images/png-country/24x24/fr.png" loading="lazy" alt="Zonebourse"></div><span class="country-name">France</span></a><a class="country-item align-center " data-edition="de_DE" href="//de.marketscreener.com/"><div class="country-flag"><img src="https://cdn.zonebourse.com/images/png-country/24x24/de.png" loading="lazy" alt="MarketScreener Deutschland"></div><span class="country-name">Deutschland</span></a><a class="country-item align-center " data-edition="fr_CH" href="//ch.zonebourse.com/"><div class="country-flag"><img src="https://cdn.zonebourse.com/images/png-country/24x24/ch.png" loading="lazy" alt="Zonebourse Suisse"></div><span class="country-name">Suisse</span></a><a class="country-item align-center " data-edition="de_CH" href="//ch.marketscreener.com/"><div class="country-flag"><img src="https://cdn.zonebourse.com/images/png-country/24x24/ch.png" loading="lazy" alt="MarketScreener Schweiz"></div><span class="country-name">Schweiz</span></a><a class="country-item align-center " data-edition="it_IT" href="//it.marketscreener.com/"><div class="country-flag"><img src="https://cdn.zonebourse.com/images/png-country/24x24/it.png" loading="lazy" alt="MarketScreener Italia"></div><span class="country-name">Italia</span></a><a class="country-item align-center " data-edition="de_AT" href="//at.marketscreener.com/"><div class="country-flag"><img src="https://cdn.zonebourse.com/images/png-country/24x24/at.png" loading="lazy" alt="MarketScreener Österreich"></div><span class="country-name">Österreich</span></a><a class="country-item align-center " data-edition="nl_BE" href="//be.marketscreener.com/"><div class="country-flag"><img src="https://cdn.zonebourse.com/images/png-country/24x24/be.png" loading="lazy" alt="MarketScreener België"></div><span class="country-name">België</span></a><a class="country-item align-center " data-edition="nl_NL" href="//nl.marketscreener.com/"><div class="country-flag"><img src="https://cdn.zonebourse.com/images/png-country/24x24/nl.png" loading="lazy" alt="MarketScreener Nederland"></div><span class="country-name">Nederland</span></a><a class="country-item align-center " data-edition="es_ES" href="//es.marketscreener.com/"><div class="country-flag"><img src="https://cdn.zonebourse.com/images/png-country/24x24/es.png" loading="lazy" alt="MarketScreener España"></div><span class="country-name">España</span></a><a class="country-item align-center " data-edition="sv_SE" href="//se.marketscreener.com/"><div class="country-flag"><img src="https://cdn.zonebourse.com/images/png-country/24x24/se.png" loading="lazy" alt="MarketScreener Sverige"></div><span class="country-name">Sverige</span></a><a class="country-item align-center " data-edition="en_GB" href="//uk.marketscreener.com/"><div class="country-flag"><img src="https://cdn.zonebourse.com/images/png-country/24x24/gb.png" loading="lazy" alt="MarketScreener UK"></div><span class="country-name">United Kingdom</span></a></div></div></div><div class="c-12 cm-3 "><div class="mb-10"><p class="region-title pl-5 mb-10">APAC</p><div class="c-flex flex-wrap countries-grid--1"><a class="country-item align-center " data-edition="en_AU" href="//au.marketscreener.com/"><div class="country-flag"><img src="https://cdn.zonebourse.com/images/png-country/24x24/au.png" loading="lazy" alt="MarketScreener Australia"></div><span class="country-name">Australia</span></a><a class="country-item align-center " data-edition="en_IN" href="//in.marketscreener.com/"><div class="country-flag"><img src="https://cdn.zonebourse.com/images/png-country/24x24/in.png" loading="lazy" alt="MarketScreener India"></div><span class="country-name">India</span></a><a class="country-item align-center " data-edition="en_HK" href="//hk.marketscreener.com/"><div class="country-flag"><img src="https://cdn.zonebourse.com/images/png-country/24x24/hk.png" loading="lazy" alt="MarketScreener Hong Kong"></div><span class="country-name">Hong Kong</span></a></div></div></div></div></div></div><div id="notifications-portal"
data-flashes="[]"
></div><div id="g_id_onload"
data-client_id="420803176712-vlrh8sjg6d8d2ljv2t5o05foig31q9qd.apps.googleusercontent.com"
data-login_uri="https://www.marketscreener.com/login/google/"
data-auto_prompt="true"
data-itp_support="true"
></div><script src="https://cdn.zonebourse.com/static/assets/mPulse/mpulse-surperformance.js" async></script><input type="hidden" id="csrf-token" value="e5b21377e1a6524eeec8bc0.dttR0k2uytvhO4QwNAde4COvnIJ4LVqVrnfHot1BDBo.RJk5gSDKvY6tVfd6Xjc0j1b7285KVA3f3z2lxaspRi0Ctx3nKf2worda4w"></body></html> |